Earn H. Gan
Earn H. Gan
Institute of Genetic Medicine, International Centre for Life, Newcastle upon Tyne, United Kingdom
Search for other papers by Earn H. Gan in
Google Scholar
PubMed
Search for other papers by Earn H. Gan in
Google Scholar
PubMed
Anna L. Mitchell
Anna L. Mitchell
Institute of Genetic Medicine, International Centre for Life, Newcastle upon Tyne, United Kingdom
Search for other papers by Anna L. Mitchell in
Google Scholar
PubMed
Search for other papers by Anna L. Mitchell in
Google Scholar
PubMed
Ruth Plummer
Ruth Plummer
Institute of Genetic Medicine, International Centre for Life, Newcastle upon Tyne, United Kingdom
Search for other papers by Ruth Plummer in
Google Scholar
PubMed
Search for other papers by Ruth Plummer in
Google Scholar
PubMed
Simon Pearce
Simon Pearce
Institute of Genetic Medicine, International Centre for Life, Newcastle upon Tyne, United Kingdom
Search for other papers by Simon Pearce in
Google Scholar
PubMed
Search for other papers by Simon Pearce in
Google Scholar
PubMed
Petros Perros
Petros Perros
Institute of Genetic Medicine, International Centre for Life, Newcastle upon Tyne, United Kingdom
Search for other papers by Petros Perros in
Google Scholar
PubMed
Search for other papers by Petros Perros in
Google Scholar
PubMed
the first 12 weeks following anti-CTLA-4 therapy. In this case, Graves disease developed after 8 years of tremelimumab therapy for metastatic melanoma. Antithyroid drug therapy was safe and effective alongside anti-CTLA-4 therapy without
Pauline Campredon
Pauline Campredon
Department of Endocrinology and Metabolic Diseases, Larrey University Hospital, Toulouse, France
Search for other papers by Pauline Campredon in
Google Scholar
PubMed
Search for other papers by Pauline Campredon in
Google Scholar
PubMed
Philippe Imbert
Philippe Imbert
Ophthalmologist, Clinique du Parc, Toulouse, France
Multidisciplinary Thyroid Eye Consultation, Department of Endocrinology, Larrey University Hospital, Toulouse, France
Search for other papers by Philippe Imbert in
Google Scholar
PubMed
Multidisciplinary Thyroid Eye Consultation, Department of Endocrinology, Larrey University Hospital, Toulouse, France
Search for other papers by Philippe Imbert in
Google Scholar
PubMed
Céline Mouly
Céline Mouly
Department of Endocrinology and Metabolic Diseases, Larrey University Hospital, Toulouse, France
Search for other papers by Céline Mouly in
Google Scholar
PubMed
Search for other papers by Céline Mouly in
Google Scholar
PubMed
Solange Grunenwald
Solange Grunenwald
Department of Endocrinology and Metabolic Diseases, Larrey University Hospital, Toulouse, France
Search for other papers by Solange Grunenwald in
Google Scholar
PubMed
Search for other papers by Solange Grunenwald in
Google Scholar
PubMed
Julien Mazières
Julien Mazières
Department of Pneumology, Larrey University Hospital, Toulouse, France
Search for other papers by Julien Mazières in
Google Scholar
PubMed
Search for other papers by Julien Mazières in
Google Scholar
PubMed
Philippe Caron
Philippe Caron
Department of Endocrinology and Metabolic Diseases, Larrey University Hospital, Toulouse, France
Search for other papers by Philippe Caron in
Google Scholar
PubMed
Search for other papers by Philippe Caron in
Google Scholar
PubMed
. Anti-cytotoxic T-lymphocytic-associated antigen-4 antibodies (ipilimumab, tremelimumab) preferentially exhibited pituitary toxicity with hypophysitis as the primary consequence. The most frequent endocrine disorders related to anti-PD-1 monoclonal
Alessandro Brancatella
Alessandro Brancatella
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Pisa, Pisa, Italy
Search for other papers by Alessandro Brancatella in
Google Scholar
PubMed
Search for other papers by Alessandro Brancatella in
Google Scholar
PubMed
Nicola Viola
Nicola Viola
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Pisa, Pisa, Italy
Search for other papers by Nicola Viola in
Google Scholar
PubMed
Search for other papers by Nicola Viola in
Google Scholar
PubMed
Sandra Brogioni
Sandra Brogioni
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Pisa, Pisa, Italy
Search for other papers by Sandra Brogioni in
Google Scholar
PubMed
Search for other papers by Sandra Brogioni in
Google Scholar
PubMed
Lucia Montanelli
Lucia Montanelli
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Pisa, Pisa, Italy
Search for other papers by Lucia Montanelli in
Google Scholar
PubMed
Search for other papers by Lucia Montanelli in
Google Scholar
PubMed
Chiara Sardella
Chiara Sardella
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Pisa, Pisa, Italy
Search for other papers by Chiara Sardella in
Google Scholar
PubMed
Search for other papers by Chiara Sardella in
Google Scholar
PubMed
Paolo Vitti
Paolo Vitti
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Pisa, Pisa, Italy
Search for other papers by Paolo Vitti in
Google Scholar
PubMed
Search for other papers by Paolo Vitti in
Google Scholar
PubMed
Claudio Marcocci
Claudio Marcocci
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Pisa, Pisa, Italy
Search for other papers by Claudio Marcocci in
Google Scholar
PubMed
Search for other papers by Claudio Marcocci in
Google Scholar
PubMed
Isabella Lupi
Isabella Lupi
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Pisa, Pisa, Italy
Search for other papers by Isabella Lupi in
Google Scholar
PubMed
Search for other papers by Isabella Lupi in
Google Scholar
PubMed
Francesco Latrofa
Francesco Latrofa
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Pisa, Pisa, Italy
Search for other papers by Francesco Latrofa in
Google Scholar
PubMed
Search for other papers by Francesco Latrofa in
Google Scholar
PubMed
Treatment of Ipilimumab Induced Graves ’ Disease in a Patient with Metastatic Melanoma. 2016 ;2016(Table 1):1–5. 12 Gan EH , Mitchell AL , Plummer R , Pearce S , Perros P . Tremelimumab-Induced Graves Hyperthyroidism. 2017 ;167
